Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for value-driven solutions.

The quest to mitigate disability progression in multiple sclerosis (MS) has long been hindered by our limited understanding ...

Tolebrutinib is one of several oral BTK drugs that have been in clinical development for MS, alongside Merck KGaA's evobrutinib, Roche's fenebrutinib, Novartis' remibrutinib, and InnoCare Pharma's ...

Tolebrutinib was one of three oral BTK inhibitors that Sanofi acquired as part of its $3.7 billion buyout of Principia Biopharma in 2020, and was abandoned as a treatment for myasthenia gravis ...

But tolebrutinib showed something novel at ECTRIMS. In the phase III HERCULES trial, tolebrutinib slowed confirmed disability progression (CDP) in people with non-relapsing secondary progressive ...

The multiple sclerosis (MS) disease-modifying therapy (DMT) market across the seven major markets (7MM: the US, France, ...

The phase III PERSEUS trial of tolebrutinib in primary progressive MS also is underway. Bermel has served as a consultant for Sanofi/Genzyme, Roche/Genentech, and Novartis.

We used the Finviz stock screener to compile a list of the top 11 drug stocks most popular among elite hedge funds. The hedge fund data was sourced from Insider Monkey’s database, which tracks ...

Tolebrutinib Long-term Data Continue to Show the BTK Inhibitor Is Safe, Clinically Effective in MS Maggie L. Shaw April 24th 2023 ...

For instance, tolebrutinib, a Bruton’s tyrosine kinase (BTK) inhibitor, is undergoing phase 3 trials to assess its potential in slowing PPMS progression.

Medical experts discuss the failure of evobrutinib to meet its primary endpoint in phase 3 trials, review the primary outcomes of the phase 2B study of tolebrutinib in relapsing multiple sclerosis ...